Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1997 1
1998 1
2000 2
2001 1
2002 10
2003 9
2004 5
2005 9
2006 4
2007 3
2008 3
2009 5
2010 9
2011 5
2012 10
2013 4
2014 7
2015 9
2016 8
2017 10
2018 2
2019 3
2020 8
2021 15
2022 9
2023 15
2024 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Results by year

Filters applied: . Clear all
Page 1
EDITORIAL COMMENT.
Nabavizadeh R, Higgins MI, Master VA, Ogan K. Nabavizadeh R, et al. Among authors: ogan k. Urology. 2021 Feb;148:124-125. doi: 10.1016/j.urology.2020.09.052. Urology. 2021. PMID: 33549204 No abstract available.
AUTHOR REPLY.
Schmeusser BN, Nicaise EH, Ogan K, Master VA. Schmeusser BN, et al. Among authors: ogan k. Urology. 2024 Jan;183:155-156. doi: 10.1016/j.urology.2023.07.052. Epub 2023 Nov 18. Urology. 2024. PMID: 37985283 No abstract available.
Reply by Authors.
Nicaise EH, Schmeusser BN, Patil DH, Ogan K, Master VA. Nicaise EH, et al. Among authors: ogan k. Urol Pract. 2023 Nov;10(6):552. doi: 10.1097/UPJ.0000000000000432.03. Epub 2023 Sep 1. Urol Pract. 2023. PMID: 37747925 No abstract available.
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702 Free article.
C-reactive protein in urologic cancers.
Huang J, Baum Y, Alemozaffar M, Ogan K, Harris W, Kucuk O, Master VA. Huang J, et al. Among authors: ogan k. Mol Aspects Med. 2015 Nov;45:28-36. doi: 10.1016/j.mam.2015.04.001. Epub 2015 Apr 29. Mol Aspects Med. 2015. PMID: 25936279 Review.
Author Reply.
Broggi MS, Patil D, Baum Y, Nieh PT, Alemozaffar M, Pattaras JG, Ogan K, Master VA. Broggi MS, et al. Among authors: ogan k. Urology. 2016 Oct;96:105. doi: 10.1016/j.urology.2016.05.066. Epub 2016 Aug 15. Urology. 2016. PMID: 27539917 No abstract available.
Reply to Pankaj N. Maheshwari, Aditya Goal, and Pushkar Srivastava's Letter to the Editor re: Manuel Armas-Phan, Benjamin N. Schmeusser, Nicholas W. Eyrich, and Kenneth Ogan. Double-J Stent Misplacement in the Inferior Vena Cava and Right Atrium: A Urovascular Nightmare. Eur Urol Open Sci 2022;46:128-34.
Schmeusser BN, Armas-Phan M, Eyrich NW, Ogan K. Schmeusser BN, et al. Among authors: ogan k. Eur Urol Open Sci. 2023 Feb 20;50:24-25. doi: 10.1016/j.euros.2023.01.014. eCollection 2023 Apr. Eur Urol Open Sci. 2023. PMID: 36874174 Free PMC article. No abstract available.
Editorial Comment.
Ogan K. Ogan K. J Urol. 2018 Apr;199(4):926. doi: 10.1016/j.juro.2017.10.059. Epub 2017 Dec 29. J Urol. 2018. PMID: 29289604 No abstract available.
162 results